Related Experiment Video
Updated: Jun 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Targeting lymphocyte activation to treat rheumatoid arthritis
Géraldine Falgarone1, Luca Semerano, Sandrine Rullé
1University of Paris 13, Li2P, EA4222, Bobigny, France. g.falgarone@avc.aphp.fr
Abstract:
The introduction of targeted treatments has radically changed the management of patients with rheumatoid arthritis (RA). Abatacept is among these new treatments emerging from recent insights into joint immunopathology. Abatacept blocks the interaction between antigen-presenting cells and T-cells, thereby diminishing T-cell activation and possibly improving overall cell regulation. In RA patients, abatacept is effective in decreasing the arthritis, pain, disability, fatigue, and radiological joint damage. Abatacept provides lasting remissions or low levels of disease activity and therefore constitutes a valuable addition to the current therapeutic armamentarium for RA, which is hoped to make a full remission an attainable goal in the overall population of RA patients.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
